Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma

Inclusion Criteria: A participant with superficial BCC lesion(s) suitable for entry was defined as a participant with: * histologically confirmed diagnosis of primary superficial BCC lesion(s) * BCC lesions suitable for cryotherapy * males or females above 18 years of age * written informed consent. In accordance with Amendment 2 (local amendment), only participant above 19 years of age were to be included in Austria. Exclusion Criteria: A participant or lesion fulfilling any of the following criteria was ineligible for inclusion: * prior treatment of the BCC lesion(s) * participant with more than 10 eligible BCC lesions * a superficial BCC lesion with the largest diameter exceeding 15 mm on face/scalp, larger than 20 mm on extremities and neck and larger than 30 mm on the trunk * a superficial BCC lesion with the largest diameter smaller than 6 mm * participant with porphyria * participant with Gorlin's syndrome * pigmented superficial BCC lesion(s) * morpheaform lesion(s) * infiltrating lesion(s) * participants with a history of arsenic exposure * known allergy to Metvix®, a similar PDT compound or excipients of the cream * participation in other clinical studies either concurrently or within the last 30 days * pregnant or breast-feeding; all women of child-bearing potential had to document a negative pregnancy test and use the pill or intrauterine device during the treatments and for at least one month thereafter * conditions associated with a risk of poor protocol co…